$374.59
−1.29%Price chart
Oct 2Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 3
Key dataNov 3, 2026
Open$371.70
From 52W high−3.04%
Volume0.00
Market cap$10.02B
P/E (TTM)45.0x
P/S (TTM)3.9x
Div yield—
Key dataNov 3, 2026
Open
$371.70
From 52W high
−3.04%
Volume
0.00
Market cap
$10.02B
ValuationView details →
P/E (Fwd)
33.6x
EV/EBITDA
18.7x
P/E (TTM)
45.0x
RSI (14)
57.2
MomentumView details →
1D Return
−1.29%
YTD Return
+20.56%
SummaryUpdated Jun 1, 2026
Bio-Rad Laboratories, Inc. (NASDAQ:BIO) is a global life sciences company founded in 1952 and headquartered in Hercules, California. The company has been publicly traded since 1980 and operates as a leading manufacturer and distributor of life science research and clinical diagnostic products worldwide. With over 70 years of experience, Bio-Rad serves customers across the United States, Europe, Asia, Canada, and Latin America through two primary business segments: Life Science and Clinical Diagnostics. The company has established itself as a key player in the biotechnology and medical diagnostics industry, providing essential tools and technologies that support scientific research, drug development, and medical testing.
Similar companies
Latest newsMore news →
First Trust Advisors LP reduced its stake in Bio-Rad Laboratories, Inc. by 97.3% during the quarter, selling 55,710 shares and retaining 1,522 shares, according to a recent SEC filing.83d agoBio-Rad Laboratories reported its financial results for the second quarter ended June 30, 2026, with reported revenue flat year-over-year, as growth in Clinical Diagnostics was offset by softness in Life Science.92d ago